X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Innovest Global Inc. Signs Letter Of Intent to Acquire Commercial Energy Business

Yuvraj_pawp by Yuvraj_pawp
28th November 2017
in Market Moves
Innovest Global Inc. Signs Letter Of Intent to Acquire Commercial Energy Business

Innovest Global Inc. announced that it has signed a Letter of Intent to acquire a Commercial Energy business, which will launch a Commercial Energy Division for the diversified holding company, and add a 7-figure revenue stream to Innovest’s top-line.

“We’re focusing on a few key industries that we believe have significant growth potential,” said Innovest CEO, Dan Martin, “Certainly, new trends and technologies make Commercial Energy an attractive opportunity, and considering our existing business to business sales division, it’s also a great strategic fit.”

The Letter of Intent is subject to a confidentiality agreement. However, Innovest is fully equipped to execute the transaction, and does not need any financial or other arrangements to close. Preliminary due diligence has been completed, and once Innovest completes final due diligence, the Parties expect the transaction to close by January, 2018.

The target company features executives, each having more than 15 years experience at the highest level in their field, and excited to join the Innovest team. After a very successful history, they expanded the business to reflect the current needs of commercial and industrial clients. They now provide an all-in-one offering: procurement, management, and efficiency solutions for commercial and industrial clients. In seven months since the expansion, the new offerings added annual run rate revenue of $1 million, which is growing rapidly. It is a scalable model, expandable geographically.

According to the 2017 Power and Utilities Trends report by PwC, current trends in the industry are a “Blueprint for a Service Based Model”, such as the model Innovest has found in this company. Energy management, emerging technologies, equipment use monitoring, are all part of a revolutionary new way of managing cost and efficiency in a technologically driven economy, with increasing energy demands. “We want to be on the front end of these trends, with an amazing team and sales momentum, and we get all three with this transaction,” said Martin.

Innovest’s diversified holding company model, and their focus on efficient customer acquisition and reduced risk, are the core tenets of what the company hopes will create significant value for their shareholders.

For more information contact
info@innovestglobal.com
Innovest, Investor Relations Matt Rego
216.815.1122
http://www.innovestglobal.com

Previous Post

Stealth BioTherapeutics Granted Fast Track Designation For The Treatment Of Barth Syndrome

Next Post

Synpromics announces collaboration with UCL to develop revolutionary gene therapy for Parkinson’s Disease

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post

Synpromics announces collaboration with UCL to develop revolutionary gene therapy for Parkinson’s Disease

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In